178 related articles for article (PubMed ID: 9622543)
1. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
[TBL] [Abstract][Full Text] [Related]
2. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
De Lucca GV; Kim UT; Liang J; Cordova B; Klabe RM; Garber S; Bacheler LT; Lam GN; Wright MR; Logue KA; Erickson-Viitanen S; Ko SS; Trainor GL
J Med Chem; 1998 Jun; 41(13):2411-23. PubMed ID: 9632373
[TBL] [Abstract][Full Text] [Related]
3. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
Lam PY; Ru Y; Jadhav PK; Aldrich PE; DeLucca GV; Eyermann CJ; Chang CH; Emmett G; Holler ER; Daneker WF; Li L; Confalone PN; McHugh RJ; Han Q; Li R; Markwalder JA; Seitz SP; Sharpe TR; Bacheler LT; Rayner MM; Klabe RM; Shum L; Winslow DL; Kornhauser DM; Hodge CN
J Med Chem; 1996 Aug; 39(18):3514-25. PubMed ID: 8784449
[TBL] [Abstract][Full Text] [Related]
4. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
Smith AB; Cantin LD; Pasternak A; Guise-Zawacki L; Yao W; Charnley AK; Barbosa J; Sprengeler PA; Hirschmann R; Munshi S; Olsen DB; Schleif WA; Kuo LC
J Med Chem; 2003 May; 46(10):1831-44. PubMed ID: 12723947
[TBL] [Abstract][Full Text] [Related]
8. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
De Lucca GV; Liang J; De Lucca I
J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
[TBL] [Abstract][Full Text] [Related]
9. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
[TBL] [Abstract][Full Text] [Related]
10. Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
Spaltenstein A; Almond MR; Bock WJ; Cleary DG; Furfine ES; Hazen RJ; Kazmierski WM; Salituro FG; Tung RD; Wright LL
Bioorg Med Chem Lett; 2000 Jun; 10(11):1159-62. PubMed ID: 10866371
[TBL] [Abstract][Full Text] [Related]
11. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
[TBL] [Abstract][Full Text] [Related]
12. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
[TBL] [Abstract][Full Text] [Related]
13. An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
Smith AB; Hirschmann R; Pasternak A; Yao W; Sprengeler PA; Holloway MK; Kuo LC; Chen Z; Darke PL; Schleif WA
J Med Chem; 1997 Aug; 40(16):2440-4. PubMed ID: 9258349
[No Abstract] [Full Text] [Related]
14. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
Lam PY; Jadhav PK; Eyermann CJ; Hodge CN; Ru Y; Bacheler LT; Meek JL; Otto MJ; Rayner MM; Wong YN
Science; 1994 Jan; 263(5145):380-4. PubMed ID: 8278812
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors.
De Lucca GV; Liang J; Aldrich PE; Calabrese J; Cordova B; Klabe RM; Rayner MM; Chang CH
J Med Chem; 1997 May; 40(11):1707-9. PubMed ID: 9171880
[TBL] [Abstract][Full Text] [Related]
17. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
Sham HL; Zhao C; Stewart KD; Betebenner DA; Lin S; Park CH; Kong XP; Rosenbrook W; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A; Saldivar A; Marsh KC; McDonald E; Wideburg NE; Denissen JF; Robins T; Kempf DJ; Plattner JJ; Norbeck DW
J Med Chem; 1996 Jan; 39(2):392-7. PubMed ID: 8558507
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.
Randolph JT; Huang PP; Flosi WJ; DeGoey D; Klein LL; Yeung CM; Flentge C; Sun M; Zhao C; Dekhtyar T; Mo H; Colletti L; Kati W; Marsh KC; Molla A; Kempf DJ
Bioorg Med Chem; 2006 Jun; 14(12):4035-46. PubMed ID: 16504523
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
